Protagonist Therapeutics reports Q3 2026 results
Item 2.02 Reports results
- Form
- 8-K
- Filed
- Importance
- Major
- Accession
- 0001104659-26-123351
- Press release titled 'Protagonist Reports Third Quarter 2026 Financial Results and Provides Corporate Update' attached as Exhibit 99.1
- No specific financial figures or details provided in the 8-K filing
Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.
The reading, claim by claim
- Under Item 2.02, the company said it reported its financial results for the quarter ended September 30, 2026 on that date.
- The results were given in a press release titled 'Protagonist Reports Third Quarter 2026 Financial Results and Provides Corporate Update.' The filing furnishes it as Exhibit 99.1 and incorporates it by reference.
- The filing says the information is not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934.
- It is signed by Asif Ali, Chief Financial Officer.
4 of 5 claims matched the filing text.
Not found in the filing text
- The 8-K text itself does not state third-quarter 2026 figures.
For perspective, checked against its own source
From the 10-Q for the quarter ended June 30, 2026
- For context, in its 10-Q for the quarter ended June 30, 2026, the company reported revenue of $213.5 million and net income of $162.8 million.
- That filing also showed an operating margin of 74.4%, a net margin of 76.3%, and a revenue change from a year earlier of +3749.2%.
From the filing
Item 2.02. Results of Operations
Item 2.02. Results of Operations and Financial Condition.
On November 5, 2026, Protagonist Therapeutics,1
Inc. (the "Company") reported its financial results for the quarter ended September 30, 2026.1 A copy of the press release titled "Protagonist Reports Third Quarter 2026 Financial Results and Provides Corporate Update" is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.2
Item 9.01. Financial Statements and Exhibits.
Item
9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
Description
99.1
Press release, dated November 5, 2026, titled "Protagonist Reports Third Quarter 2026 Financial Results and Provides Corporate Update.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
The information in this report, including the exhibits hereto, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended3, or otherwise subject to the liabilities of Section 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibits shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Protagonist Therapeutics, Inc., whether made before or after the date hereof, regardless of any general incorporation language in such filing.
SIGNATURE
Pursuant to the requirements of the Securities Exchange
Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Protagonist Therapeutics, Inc.
Dated: November 5, 2026
By:
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- Prestige Consumer Healthcare PBH public float $3.0B, Sep 30, 2025
- Viking Therapeutics VKTX public float $3.0B, Jun 30, 2025
- Catalyst Pharmaceuticals CPRX public float $2.5B, Jun 30, 2025
- Cytokinetics CYTK public float $2.5B, Jun 30, 2025
- TG Therapeutics TGTX public float $2.5B, Jun 30, 2025